Project title: Phase 1 study of SurVaxM ™ in survivin positive nets

Renuka Iyer, MD Roswell Park Comprehensive Cancer Center

Renuka Iyer, MD
  • Status: Active
  • Year(s): 202018
  • Grant Type: Pilot
  • Research Type: Clinical
  • Primary Tumor Site: Small intestine
  • Area of Inquiry: Clinical trials

General Description

This study tests the immunotherapy SurVaxM in combination with a somatostatin analog in patients with survivin-expressing NETs. The vaccine targets survivin, a protein that’s often highly expressed in lung, intestinal, and pancreatic NETs and associated with aggressive disease because of its ability to prevent tumor cell death. Many patients with incurable brain cancers on SurvaxM have shown better outcomes than would be expected with standard of care alone.

Additional Details

  • City: Buffalo
  • Grant Duration: 1 year
« Back to all funded research projects